From Nanomolar to Picomolar: A Research Program Refines Amylase Inhibitors for Diabetes
- A conspectus recounting a research program to design small-molecule inhibitors of human pancreatic α-amylase, key to starch digestion and post-meal glucose spikes.
- Frames the work against the rising global burden of type 2 diabetes and its glycemic complications.
- Traces iterative structure-based design that pushed inhibitor affinity from nanomolar into the picomolar range.
- Discusses translational potential of these ultra-potent inhibitors for managing postprandial hyperglycemia.
💡 Points
Picomolar affinity against an enzyme sitting in the gut lumen is a flex, but for pancreatic α-amylase the win isn't classic PK — it's durable target engagement at low dose. The translational question this conspectus glosses over: does that ultra-potency actually cut the GI side-effect burden that's dogged amylase inhibitors like acarbose, or just move the goalposts on Ki.